Tax medication, a high -risk shine for the United States – RTS.CH

Can it really do it? Therefore, This question agitates American political. Similarly, economic circles since Donald Trump spoke of the possibility of imposing up to 250% customs duties on imported drugs. Moreover, A thunderous announcement. Therefore. Therefore. Furthermore. Consequently, faithful to the style of the former president, but whose implementation raises many questions, both on the feasibility and the consequences for the health of American citizens.

&gt. For example. Furthermore. However, > On this subject: Donald Trump demands that the pharmas will drop tax medication, high -risk shine new their prices tax medication, high -risk shine new under penalty tax medication, high -risk shine new of sanctions

Produce on American soil – Tax medication, high -risk shine – Tax medication, high -risk shine new

Like what he has already started with semiconductors. However, Donald Trump clearly displays his intention to repatriate pharmaceutical production tax medication, high -risk shine on American soil. Consequently, According to Jérôme Schupp. In addition. For example. For example. Furthermore, financial analyst specializing in the sector at Prime Partners, “the priority objective is not necessarily the drop in prices, but the incentive to invest and produce in the United States. Nevertheless, This is exactly what Apple did, for example, which has just announced 100 billion dollars of investments on American soil.”

For Valérie Junod. Consequently. However. Therefore. Consequently, professor in pharmaceutical law at the University of Lausanne, this plan follows an understandable economic logic: “Production takes place today mainly tax medication, high -risk shine new in Asia. In addition. However. The aim is to repatriate tax medication, high -risk shine new not only manufacturing, but also pharmaceutical research, already partly present in the United States.” The American Johnson & tax medication, high -risk shine new Johnson. Similarly. Consequently, just like the Swiss Roche. Novartis [qui réalisent près de 50% de leur chiffre d’affaires aux Etats-Unis. ndlr], have already shown white legs by announcing massive investments on American soil.

>> Read also: Pharma tax medication, high -risk shine Basel under pressure between Trump. more virulent competition

At the end of April already. the director general of Roche Thomas Schinecker had declared to the press that four portfolio drugs alone represented 92%. of the company’s exposure to American customs rights. “Production in the United States is already sufficient for three of these drugs. The company has started to transfer technology for the fourth, which has never been tax medication, high -risk shine new produced across the Atlantic. drugs. which leaves him “a big room for maneuver to increase production tax medication, high -risk shine new in the United States,” said Thomas Schinecker.

A threat above all political – Tax medication. high -risk shine – Tax medication. high -risk shine new – Tax medication. Additionally, high -risk shine new – Tax medication, high -risk shine new

Tax medication, high -risk shine new

The fact remains that inflicting 250% customs duties tax medication, high -risk shine new over already very expensive drugs would be economically. untenable for American households. But as a political threat. it is formidably effective: “It would be impossible to pass on such a tax without making certain treatments inaccessible. But as a signal sent to multinationals, it works”, confirms Valérie Junod.

Same analysis tax medication. high -risk shine on the side of Jérôme Schupp: “Trump uses the method of the usual punch: threat. pressure, uncertainty. He knows that his legal room for tax medication, high -risk shine new maneuver is very low. otherwise he would have already imposed price reductions on medication for a long time”.

An American system locked by the private

The main obstacle to the price drop lies in the extreme complexity tax medication. high -risk shine new of the. American pharmaceutical market. where prices are individually negotiated between laboratories, insurers, distributors and hospitals.

“There is no central regulation as in Europe,” explains Jérôme Schupp. “It is a completely private market. Trump does not attack civil tax medication. high -risk shine new servants there, but powerful economic actors, including American economic players.” According to Valérie Junod. touching the agreements in place would involve renegotiating hundreds of thousands of contracts, a titanic task.

>> Read on this subject: Why are drugs so expensive in the United States?

In addition. from a legal point of view. introduce a tax medication. high -risk shine clause like that of the “most favored tax medication, high -risk shine new nation” [payer. aux Etats-Unis, le prix le plus bas pratiqué dans un autre pays, ndlr] would be an administrative and legal nightmare. Valérie Junod specifies: “For example. some pharmaceutical companies could turn around. complaining that it is a form of expropriation tax medication, high -risk shine new of their rights. since it was a free market which has become a market controlled by the State …”

Break the value chain

Behind the announcement effect, manufacturers are concerned about a scenario with counterproductive effects. By too strongly threatening the profitability of the sector. tax medication. high -risk shine new Donald Trump may break the dynamics of innovation. essential for the sector and in particular in the United States.

&gt. &gt. Read also: The end of American investments in mRNA vaccines is “a hard blow” for the WHO

“To put. your hand in the gear of the pharmacy is to risk causing short -term tax medication, high -risk shine new shortages. as we have seen during tax medication, high -risk shine the covid,” warns Jérôme Schupp. “And in the long term, it is less research and development, therefore fewer promising new drugs. If we break this channel. it is the American citizen who will pay the price. tax medication. high -risk shine new by a reduced access to treatments and a drop in innovation,” insists the financial analyst.

Threatened biotech. America too

The stake is not only sanitary: it is the whole place of world leader in the United States. in the Pharma. the Biotech that is at stake. “If you discourage scientists from tax medication, high -risk shine new coming to the United States. you hypotheque an entire part of the country’s future growth,” notes Jérôme Schupp. “Today, a biotech first thinks of the American market to launch its molecule.”

In this context, too strong pressure could weaken the national pharmaceutical ecosystem, tax medication, high -risk shine new creator of jobs and exports.

A bet that could turn against him

Donald Trump makes the medicine a workhorse. But by threatening a complex. tax medication. high -risk shine strategic. fundamentally private sector, he plays politically large: the pharmacy is a powerful lobby, traditionally on the republican side. And above all a big provider of tax medication, high -risk shine new donations during electoral campaigns.

Between potential shortages. decline in research. destabilization of the supply chain, the American patient could end up being the main victim of this showdown.

Cécile Denayrouse